During Tuesday’s State of the Union address, President Trump pledged to drive down drug prices.
That’s a worthy goal. And fortunately, the Trump administration is already pursuing it in a way that protects patients and encourages research and development. Many of the strategies that candidate Trump proposed on the campaign trail would have done more harm than good.
Candidate Trump often agreed with Hillary Clinton and Sen. Bernie Sanders on drug prices. They all wanted to repeal Medicare Part D’s “non-interference clause,” which prevents the federal government from negotiating drug prices directly with manufacturers. Private insurers currently handle negotiations for Part D, a prescription drug program that benefits about 42 million Americans.
Such interference wouldn’t result in lower prices. Private insurers already extract major discounts from drug companies. Giving federal bureaucrats the power to negotiate prices “would have a negligible effect on Medicare drug spending,” according to the nonpartisan Congressional Budget Office.
Federal negotiators would only be able to obtain lower prices by establishing a national formulary of preferred drugs. That would make many medications completely inaccessible for seniors.
Just ask veterans. The Department of Veterans Affairs healthcare system uses such a formulary. As a result, veterans don’t have access to nearly 20 percent of the most commonly prescribed drugs under Medicare Part D.
Candidate Trump also advocated for drug price controls. But imposing such caps would hinder efforts to develop breakthrough medications, as pharmaceutical companies would struggle to justify research expenditures. Indeed, nations that rely on price controls to artificially keep prices low are effectively, and unfairly, free-riding on U.S. patients, who fund the bulk of medical research and development. The average new medicine costs about $2.6 billion to bring to market.
Thankfully, the Trump administration jettisoned these counterproductive policy proposals. It’s now pursuing measures that curb costs while improving the overall quality of healthcare.
Consider the president’s reauthorization of PDUFA, a 1992 law that allows the Food and Drug Administration to charge pharmaceutical companies for reviewing drug applications. This extra revenue enables the FDA to review applications faster. As a result, more medications make it to market sooner — opening up options for consumers and lowering prices through competition.
Another promising step is a proposed rule from the Centers for Medicare and Medicaid Services. The rule would curb price gouging by pharmacy benefit managers. These middlemen negotiate with drug manufacturers to obtain price discounts for insurance companies.
PBMs use their bulk buying power to extract massive rebates from drug makers. From 2010 to 2015, the value of those rebates increased by more than 20 percent every year. But patients picking up their prescriptions at the drugstore often don’t benefit from these rebates — and as a result, their out-of-pocket costs remain sky-high.
The rule would require PBMs to pass along some of these rebates to Medicare patients. Beneficiaries could pocket more than $10 billion in total savings, according to estimates from CMS.
The biggest reforms are taking place at the FDA.
Commissioner Scott Gottlieb has endorsed “adaptive” clinical trials, which allow researchers to adjust experimental drug tests based on real-world evidence. This speeds up the R&D process and results in big savings for drug companies, more drug applications for the FDA, and more options for patients. More drugs on the market forces manufacturers to compete on price.
Commissioner Gottlieb has also accelerated the generic drug approval process. The FDA approved 1,027 generics in 2017 — a record high. More product choices spark price wars, a boon for patients.
On the campaign trail, candidate Trump promised he would deliver lower drug prices. Only a year into his presidency, he’s on his way to achieving that goal, thanks to his abandonment of statist price controls and an embrace of free-market reforms.
Read more . . .
Trump Already Making Progress on Making Prescription Drugs Affordable
Sally C. Pipes
During Tuesday’s State of the Union address, President Trump pledged to drive down drug prices.
That’s a worthy goal. And fortunately, the Trump administration is already pursuing it in a way that protects patients and encourages research and development. Many of the strategies that candidate Trump proposed on the campaign trail would have done more harm than good.
Candidate Trump often agreed with Hillary Clinton and Sen. Bernie Sanders on drug prices. They all wanted to repeal Medicare Part D’s “non-interference clause,” which prevents the federal government from negotiating drug prices directly with manufacturers. Private insurers currently handle negotiations for Part D, a prescription drug program that benefits about 42 million Americans.
Such interference wouldn’t result in lower prices. Private insurers already extract major discounts from drug companies. Giving federal bureaucrats the power to negotiate prices “would have a negligible effect on Medicare drug spending,” according to the nonpartisan Congressional Budget Office.
Federal negotiators would only be able to obtain lower prices by establishing a national formulary of preferred drugs. That would make many medications completely inaccessible for seniors.
Just ask veterans. The Department of Veterans Affairs healthcare system uses such a formulary. As a result, veterans don’t have access to nearly 20 percent of the most commonly prescribed drugs under Medicare Part D.
Candidate Trump also advocated for drug price controls. But imposing such caps would hinder efforts to develop breakthrough medications, as pharmaceutical companies would struggle to justify research expenditures. Indeed, nations that rely on price controls to artificially keep prices low are effectively, and unfairly, free-riding on U.S. patients, who fund the bulk of medical research and development. The average new medicine costs about $2.6 billion to bring to market.
Thankfully, the Trump administration jettisoned these counterproductive policy proposals. It’s now pursuing measures that curb costs while improving the overall quality of healthcare.
Consider the president’s reauthorization of PDUFA, a 1992 law that allows the Food and Drug Administration to charge pharmaceutical companies for reviewing drug applications. This extra revenue enables the FDA to review applications faster. As a result, more medications make it to market sooner — opening up options for consumers and lowering prices through competition.
Another promising step is a proposed rule from the Centers for Medicare and Medicaid Services. The rule would curb price gouging by pharmacy benefit managers. These middlemen negotiate with drug manufacturers to obtain price discounts for insurance companies.
PBMs use their bulk buying power to extract massive rebates from drug makers. From 2010 to 2015, the value of those rebates increased by more than 20 percent every year. But patients picking up their prescriptions at the drugstore often don’t benefit from these rebates — and as a result, their out-of-pocket costs remain sky-high.
The rule would require PBMs to pass along some of these rebates to Medicare patients. Beneficiaries could pocket more than $10 billion in total savings, according to estimates from CMS.
The biggest reforms are taking place at the FDA.
Commissioner Scott Gottlieb has endorsed “adaptive” clinical trials, which allow researchers to adjust experimental drug tests based on real-world evidence. This speeds up the R&D process and results in big savings for drug companies, more drug applications for the FDA, and more options for patients. More drugs on the market forces manufacturers to compete on price.
Commissioner Gottlieb has also accelerated the generic drug approval process. The FDA approved 1,027 generics in 2017 — a record high. More product choices spark price wars, a boon for patients.
On the campaign trail, candidate Trump promised he would deliver lower drug prices. Only a year into his presidency, he’s on his way to achieving that goal, thanks to his abandonment of statist price controls and an embrace of free-market reforms.
Read more . . .
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.